From Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK:

0220-NURTEC-D20028-RT-V1

0220-NURTEC-D20028-RT-V1—

Photo by Biohaven Pharmaceutical

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

Sponsored · Whitepaper
Potency Assay Development for Cell and Gene Therapy Products
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems

From Our Editors · Special Report
Xcelerating Life Sciences San Francisco: Special Report
The AI, Big Data, and R&D Boom

Xconomy on Demand

We offer a number of ways to subscribe for free!